tetano
Editor, Senior Moderator
Intern Med
. 2022 Nov 9.
doi: 10.2169/internalmedicine.0590-22. Online ahead of print.
New-onset Adult-onset Still's Disease Following COVID-19 Vaccination: Three Case Reports and a Literature Review
Mayumi Matsuda[SUP] 1 [/SUP], Yu Funakubo Asanuma[SUP] 1 [/SUP], Kazuhiro Yokota[SUP] 1 [/SUP], Sakon Sakai[SUP] 1 [/SUP], Hiroaki Yazawa[SUP] 1 [/SUP], Takashi Maruyama[SUP] 1 [/SUP], Takuma Tsuzuki Wada[SUP] 1 [/SUP], Yasuto Araki[SUP] 1 [/SUP], Toshihide Mimura[SUP] 1 [/SUP]
Affiliations
Abstract
Since December 2020, coronavirus disease 2019 (COVID-19) vaccines have been distributed in most countries to prevent the onset and aggravation of COVID-19. There is little information regarding the long-term safety of the vaccines. We report three cases and a literature review of new-onset adult-onset Still's disease (AOSD) that occurred following COVID-19 vaccination. Our cases include moderate to severe AOSD, and two were complicated with macrophage activation syndrome. Seventeen cases of new-onset or relapse of AOSD following COVID-19 vaccination, including 14 identified in the literature review and our 3 patients, were all treated successfully with glucocorticoid therapy, immunosuppressive drugs, or biologic agents.
Keywords: Adult-onset Still's disease; COVID-19 vaccine; Innate immune response.
. 2022 Nov 9.
doi: 10.2169/internalmedicine.0590-22. Online ahead of print.
New-onset Adult-onset Still's Disease Following COVID-19 Vaccination: Three Case Reports and a Literature Review
Mayumi Matsuda[SUP] 1 [/SUP], Yu Funakubo Asanuma[SUP] 1 [/SUP], Kazuhiro Yokota[SUP] 1 [/SUP], Sakon Sakai[SUP] 1 [/SUP], Hiroaki Yazawa[SUP] 1 [/SUP], Takashi Maruyama[SUP] 1 [/SUP], Takuma Tsuzuki Wada[SUP] 1 [/SUP], Yasuto Araki[SUP] 1 [/SUP], Toshihide Mimura[SUP] 1 [/SUP]
Affiliations
- PMID: 36351580
- DOI: 10.2169/internalmedicine.0590-22
Abstract
Since December 2020, coronavirus disease 2019 (COVID-19) vaccines have been distributed in most countries to prevent the onset and aggravation of COVID-19. There is little information regarding the long-term safety of the vaccines. We report three cases and a literature review of new-onset adult-onset Still's disease (AOSD) that occurred following COVID-19 vaccination. Our cases include moderate to severe AOSD, and two were complicated with macrophage activation syndrome. Seventeen cases of new-onset or relapse of AOSD following COVID-19 vaccination, including 14 identified in the literature review and our 3 patients, were all treated successfully with glucocorticoid therapy, immunosuppressive drugs, or biologic agents.
Keywords: Adult-onset Still's disease; COVID-19 vaccine; Innate immune response.